Header

UZH-Logo

Maintenance Infos

Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study


Weigert, G; Michels, S; Sacu, S; Varga, A; Prager, F; Geitzenauer, W; Schmidt-Erfurth, U (2008). Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology, 92(3):356-360.

Statistics

Citations

Dimensions.ai Metrics
68 citations in Web of Science®
76 citations in Scopus®
101 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

117 downloads since deposited on 21 Nov 2008
14 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:March 2008
Deposited On:21 Nov 2008 13:21
Last Modified:18 Feb 2018 09:44
Publisher:BMJ Publishing Group
ISSN:0007-1161
OA Status:Hybrid
Publisher DOI:https://doi.org/10.1136/bjo.2007.125823
PubMed ID:18303156

Download

Download PDF  'Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study'.
Preview
Filetype: PDF (Verlags-PDF)
Size: 1MB
View at publisher